ARCT
Price
$13.78
Change
+$0.16 (+1.17%)
Updated
Jul 3 closing price
Capitalization
373.72M
38 days until earnings call
RGNX
Price
$8.74
Change
+$0.12 (+1.39%)
Updated
Jul 3 closing price
Capitalization
440.4M
25 days until earnings call
Interact to see
Advertisement

ARCT vs RGNX

Header iconARCT vs RGNX Comparison
Open Charts ARCT vs RGNXBanner chart's image
Arcturus Therapeutics Holdings
Price$13.78
Change+$0.16 (+1.17%)
Volume$172.65K
Capitalization373.72M
REGENXBIO
Price$8.74
Change+$0.12 (+1.39%)
Volume$423.94K
Capitalization440.4M
ARCT vs RGNX Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. RGNX commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and RGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (ARCT: $13.78 vs. RGNX: $8.74)
Brand notoriety: ARCT and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 38% vs. RGNX: 38%
Market capitalization -- ARCT: $373.72M vs. RGNX: $440.4M
ARCT [@Biotechnology] is valued at $373.72M. RGNX’s [@Biotechnology] market capitalization is $440.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARCT and RGNX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 4 bearish.
  • RGNX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than RGNX.

Price Growth

ARCT (@Biotechnology) experienced а -4.37% price change this week, while RGNX (@Biotechnology) price change was -0.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ARCT is expected to report earnings on Aug 11, 2025.

RGNX is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($440M) has a higher market cap than ARCT($374M). RGNX YTD gains are higher at: 13.066 vs. ARCT (-18.798). ARCT has higher annual earnings (EBITDA): -63.92M vs. RGNX (-122.44M). RGNX has more cash in the bank: 268M vs. ARCT (217M). ARCT has less debt than RGNX: ARCT (42.7M) vs RGNX (79.8M). RGNX has higher revenues than ARCT: RGNX (157M) vs ARCT (131M).
ARCTRGNXARCT / RGNX
Capitalization374M440M85%
EBITDA-63.92M-122.44M52%
Gain YTD-18.79813.066-144%
P/E RatioN/AN/A-
Revenue131M157M83%
Total Cash217M268M81%
Total Debt42.7M79.8M54%
FUNDAMENTALS RATINGS
ARCT vs RGNX: Fundamental Ratings
ARCT
RGNX
OUTLOOK RATING
1..100
1155
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
5255
P/E GROWTH RATING
1..100
10023
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (47) in the Pharmaceuticals Major industry is in the same range as RGNX (73) in the Biotechnology industry. This means that ARCT’s stock grew similarly to RGNX’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as RGNX (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to RGNX’s over the last 12 months.

ARCT's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as RGNX (96) in the Biotechnology industry. This means that ARCT’s stock grew similarly to RGNX’s over the last 12 months.

ARCT's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as RGNX (55) in the Biotechnology industry. This means that ARCT’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (23) in the Biotechnology industry is significantly better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew significantly faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTRGNX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AWLIF0.140.01
+9.72%
AMERIWEST LITHIUM INC
SFTBF76.261.61
+2.16%
Softbank Group Corp
IAUFF0.19N/A
N/A
AIC Mines Ltd.
ALFNF15.20N/A
N/A
Alfen NV
RXEEY30.93-0.01
-0.03%
Rexel SA

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with TRDA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+1.17%
TRDA - ARCT
52%
Loosely correlated
N/A
ABCL - ARCT
51%
Loosely correlated
+1.33%
RXRX - ARCT
51%
Loosely correlated
+1.15%
RGNX - ARCT
51%
Loosely correlated
+1.39%
MRNA - ARCT
50%
Loosely correlated
+0.69%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with DNLI. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+1.39%
DNLI - RGNX
55%
Loosely correlated
-1.41%
BEAM - RGNX
54%
Loosely correlated
+0.65%
ARWR - RGNX
54%
Loosely correlated
-0.65%
VYGR - RGNX
52%
Loosely correlated
N/A
ALEC - RGNX
51%
Loosely correlated
+0.67%
More